Literature DB >> 10427155

Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome.

K Godang1, T Ueland, J Bollerslev.   

Abstract

It is well established that chronic excess of glucocorticoids has negative effects on bone and collagen turnover, and that secondary osteoporosis is a known clinical complication of endogenous Cushing's syndrome (CS). The aim of the present study was to evaluate bone dimension and bone mineral content in relation to biochemical markers of bone and collagen turnover, in a consecutive series of 23 patients with endogenous CS (18 with pituitary adenoma and 5 with adrenal tumor; 17 women, 6 men; mean age 39.7+/-2.8 (S.E. M.) and 44.3+/-3.1 years respectively), compared with 23 age-, sex- and body mass index-matched healthy controls. Bone mineral densities were uniformly reduced in the different regions analyzed: lumbar spine (16.1%, P<0.001), femoral neck (15.2%, P<0.001), total body (11.5%, P<0.001), and the subregions of arms (8.4%, P<0.05), legs (10.1%, P<0.05) and trunk (15.8%, P<0.001). Similar results were observed for bone mineral content, although these were less prominent. The calculated area was significantly decreased in trunk (13.8%, P<0.01) and total body (11.6%, P<0.05). Serum levels of osteocalcin were significantly decreased (28%, P<0.03) in patients with CS. No significant differences were observed for the formative markers carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type I procollagen. Markers of bone resorption, serum Crosslaps and carboxyterminal cross-linked telopeptide of type I collagen were increased in patients compared with controls, although only significantly for Crosslaps (P<0.02). No correlations between formative and resorptive markers were found in the patients, but in controls, the formative markers were positively correlated with resorptive markers. In conclusion, bone dimension and bone mineral content of the entire skeleton are found to be decreased in endogenous CS. As judged by biochemical markers of bone remodeling, this is caused by decreased bone formation and an increased bone resorption.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10427155     DOI: 10.1530/eje.0.1410126

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  15 in total

1.  Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study.

Authors:  Akiko Kawamata; Masatoshi Iihara; Takahiro Okamoto; Takao Obara
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

2.  Urinary deoxypyridinoline is a BMD-independent marker for prevalent vertebral fractures in postmenopausal women treated with glucocorticoid.

Authors:  H Kaji; M Yamauchi; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2009-11-14       Impact factor: 4.507

3.  Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease.

Authors:  S Scommegna; J P Greening; H L Storr; K M Davies; N J Shaw; J P Monson; A B Grossman; M O Savage
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

4.  Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines.

Authors:  Gherardo Mazziotti; Anna Maria Formenti; Robert A Adler; John P Bilezikian; Ashley Grossman; Emilia Sbardella; Salvatore Minisola; Andrea Giustina
Journal:  Endocrine       Date:  2016-10-20       Impact factor: 3.633

5.  Effects of Cushing disease on bone mineral density in a pediatric population.

Authors:  Maya B Lodish; Hui-Pin Hsiao; Anastasios Serbis; Ninet Sinaii; Anya Rothenbuhler; Margaret F Keil; Sosipatros A Boikos; James C Reynolds; Constantine A Stratakis
Journal:  J Pediatr       Date:  2010-03-10       Impact factor: 4.406

6.  Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome.

Authors:  J Majnik; N Szücs; A Patócs; M Tóth; K Balogh; I Varga; E Gláz; K Rácz
Journal:  J Endocrinol Invest       Date:  2004-09       Impact factor: 4.256

7.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

Review 8.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

9.  Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome.

Authors:  L Füto; J Toke; A Patócs; A Szappanos; I Varga; E Gláz; Z Tulassay; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2007-11-28       Impact factor: 4.507

Review 10.  Quality of life and other outcomes in children treated for Cushing syndrome.

Authors:  Margaret F Keil
Journal:  J Clin Endocrinol Metab       Date:  2013-05-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.